A framework for multi-scale intervention modeling: virtual cohorts, virtual clinical trials, and model-to-model comparisons

Christian T. Michael, Sayed A. Almohri, J. Linderman, Denise E. Kirschner
{"title":"A framework for multi-scale intervention modeling: virtual cohorts, virtual clinical trials, and model-to-model comparisons","authors":"Christian T. Michael, Sayed A. Almohri, J. Linderman, Denise E. Kirschner","doi":"10.3389/fsysb.2023.1283341","DOIUrl":null,"url":null,"abstract":"Computational models of disease progression have been constructed for a myriad of pathologies. Typically, the conceptual implementation for pathology-related in silico intervention studies has been ad hoc and similar in design to experimental studies. We introduce a multi-scale interventional design (MID) framework toward two key goals: tracking of disease dynamics from within-body to patient to population scale; and tracking impact(s) of interventions across these same spatial scales. Our MID framework prioritizes investigation of impact on individual patients within virtual pre-clinical trials, instead of replicating the design of experimental studies. We apply a MID framework to develop, organize, and analyze a cohort of virtual patients for the study of tuberculosis (TB) as an example disease. For this study, we use HostSim: our next-generation whole patient-scale computational model of individuals infected with Mycobacterium tuberculosis. HostSim captures infection within lungs by tracking multiple granulomas, together with dynamics occurring with blood and lymph node compartments, the compartments involved during pulmonary TB. We extend HostSim to include a simple drug intervention as an example of our approach and use our MID framework to quantify the impact of treatment at cellular and tissue (granuloma), patient (lungs, lymph nodes and blood), and population scales. Sensitivity analyses allow us to determine which features of virtual patients are the strongest predictors of intervention efficacy across scales. These insights allow us to identify patient-heterogeneous mechanisms that drive outcomes across scales.","PeriodicalId":73109,"journal":{"name":"Frontiers in systems biology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in systems biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fsysb.2023.1283341","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Computational models of disease progression have been constructed for a myriad of pathologies. Typically, the conceptual implementation for pathology-related in silico intervention studies has been ad hoc and similar in design to experimental studies. We introduce a multi-scale interventional design (MID) framework toward two key goals: tracking of disease dynamics from within-body to patient to population scale; and tracking impact(s) of interventions across these same spatial scales. Our MID framework prioritizes investigation of impact on individual patients within virtual pre-clinical trials, instead of replicating the design of experimental studies. We apply a MID framework to develop, organize, and analyze a cohort of virtual patients for the study of tuberculosis (TB) as an example disease. For this study, we use HostSim: our next-generation whole patient-scale computational model of individuals infected with Mycobacterium tuberculosis. HostSim captures infection within lungs by tracking multiple granulomas, together with dynamics occurring with blood and lymph node compartments, the compartments involved during pulmonary TB. We extend HostSim to include a simple drug intervention as an example of our approach and use our MID framework to quantify the impact of treatment at cellular and tissue (granuloma), patient (lungs, lymph nodes and blood), and population scales. Sensitivity analyses allow us to determine which features of virtual patients are the strongest predictors of intervention efficacy across scales. These insights allow us to identify patient-heterogeneous mechanisms that drive outcomes across scales.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
多尺度干预建模框架:虚拟队列、虚拟临床试验和模型间比较
人们已经为各种病症构建了疾病进展的计算模型。通常情况下,与病理学相关的硅学干预研究的概念实施是临时性的,在设计上与实验研究类似。我们引入了多尺度干预设计(MID)框架,以实现两个关键目标:追踪从体内到患者再到人群的疾病动态;以及追踪干预措施在这些相同空间尺度上的影响。我们的 MID 框架优先考虑在虚拟临床前试验中调查对单个患者的影响,而不是复制实验研究的设计。我们应用 MID 框架来开发、组织和分析虚拟患者队列,以肺结核(TB)为例进行研究。在这项研究中,我们使用了 HostSim:我们的下一代结核分枝杆菌感染者全病人尺度计算模型。HostSim 通过跟踪多个肉芽肿以及肺结核期间涉及的血液和淋巴结区的动态变化来捕捉肺部感染情况。我们对 HostSim 进行了扩展,将一种简单的药物干预作为我们方法的一个实例,并使用我们的 MID 框架来量化治疗对细胞和组织(肉芽肿)、患者(肺、淋巴结和血液)以及人群的影响。通过敏感性分析,我们可以确定虚拟患者的哪些特征是各尺度干预效果的最强预测因素。这些洞察力使我们能够确定驱动各尺度结果的患者异质性机制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Transporter annotations are holding up progress in metabolic modeling Life’s building blocks: the modular path to multiscale complexity Coupling quantitative systems pharmacology modelling to machine learning and artificial intelligence for drug development: its pAIns and gAIns Predicting chronic responses to calcium channel blockade with a virtual population of African Americans with hypertensive chronic kidney disease Building an Adverse Outcome Pathway network for COVID-19
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1